Key Highlights
- 26.74% of the float in POET Technologies (NASDAQ:POET) is sold short, with 3.2 days to cover, per published market data on October 16, 2026 intraday. FINRA data for September 30, 2026 shows 24.3 million shares short, 18.3% of shares outstanding.
- USD 5.89 was the intraday price on October 16, 2026, down 1.91% on the session and 71.7% below the 52-week high of USD 20.81 (own arithmetic). A reported Marvell order cancellation and a USD 400 million offering at USD 21 preceded the slide.
- USD 796.3 million of cash and short-term investments at June 30, 2026, per the second quarter release dated August 13, 2026, equals 78% of the USD 1.02 billion table market capitalisation (own arithmetic). Quarterly revenue was USD 569,925.
- USD 50 million is the initial Lumilens purchase order under the May 14, 2026 agreement, with potential purchases above USD 500 million over five years. Engineering samples are expected in late 2026; the third quarter results date is not confirmed.
Price Action and the Squeeze Setup
The market is paying USD 1.02 billion for a company that reported USD 569,925 of quarterly revenue, and a quarter of the float is borrowed and sold. Annualised revenue of USD 2.28 million puts the table market capitalisation at 447 times sales (own arithmetic). Days to cover is shares short divided by average daily volume, so 3.2 means a short position equal to 3.2 sessions of volume, a low figure that limits how long a squeeze could last. Short interest fell from 30.6 million shares on May 15, 2026 to 22.2 million on August 31, then rose to 24.3 million. No company-specific catalyst was identified in the filings and releases reviewed through October 16, 2026.
Why Shorts Are Positioned
Wolfpack Research published a short report on April 14, 2026 citing a seventh business pivot, repeated dilution and a price to sales ratio of 1,140. A class action filed April 29, 2026 alleges misleading statements on passive foreign investment company status. Marvell (NASDAQ:MRVL) was reported to have cancelled its purchase orders in late April. Dilution is the mechanism: the May registered direct offering issued 19,047,620 units at USD 21 with warrants at USD 26.25 until May 18, 2029, and Lumilens holds a warrant for up to 22,921,408 shares at USD 8.25, of which 2,292,140 are exercisable now.
Cash, Catalysts and Risks
Cash is not the constraint. The second quarter net loss was USD 11.3 million, so USD 796.3 million covers 70 quarters of that loss (own arithmetic), though capacity spending will raise burn. The company stated the production ramp remains on schedule for the second half of 2026. Risks include customer concentration, pending class actions, warrant overhang, and one covering analyst with a USD 8.00 target and a Sell consensus per published market data.
Where Things Stand
A squeeze is possible but not indicated: POET Technologies (NASDAQ:POET) has high short interest and fell 1.91% intraday on October 16, 2026, with no catalyst forcing shorts to cover. Short interest is 18.3% to 26.74% depending on the base, and days to cover is 3.2. Against that, cash equals 78% of market value, and the Lumilens order gives investors a testable milestone. The next dated events are engineering samples expected in late 2026 and third quarter results, whose date is not confirmed in the filings reviewed.





_11_13_2026_20_30_45_840725.jpg)
Please wait processing your request...